Equities

Kidswell Bio Corp

4584:TYO

Kidswell Bio Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)126.00
  • Today's Change-3.00 / -2.33%
  • Shares traded261.10k
  • 1 Year change-27.59%
  • Beta1.6854
Data delayed at least 20 minutes, as of Sep 20 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of JPY
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments2,2311,0671,187
Total Receivables, Net8811,089462
Total Inventory876635989
Prepaid expenses747833496
Other current assets, total18872193
Total current assets4,9243,6973,326
Property, plant & equipment, net1.321.481.64
Goodwill, net------
Intangibles, net1.532.303.06
Long term investments138173155
Note receivable - long term------
Other long term assets202118
Total assets5,0863,8953,503
LIABILITIES
Accounts payable8515645
Accrued expenses1.331.26--
Notes payable/short-term debt000
Current portion long-term debt/capital leases73737575
Other current liabilities, total1,5525241,008
Total current liabilities2,3751,0561,129
Total long term debt1,8381,575625
Total debt2,5751,950700
Deferred income tax------
Minority interest------
Other liabilities, total413031
Total liabilities4,2542,6611,785
SHAREHOLDERS EQUITY
Common stock2,0371,5091,421
Additional paid-in capital11,34210,81510,727
Retained earnings (accumulated deficit)(12548)(11091)(10429)
Treasury stock - common(0.07)(0.07)(0.07)
Unrealized gain (loss)------
Other equity, total0.00--0.00
Total equity8311,2341,719
Total liabilities & shareholders' equity5,0863,8953,503
Total common shares outstanding393231
Treasury shares - common primary issue0.000.000.00
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.